Artificial Intelligence Framework May Predict ARDS in COVID-19
Data from patients with COVID-19 can be used to develop a model that can predict who will develop acute respiratory distress syndrome.
Diagnostic Testing
Home Assessment Teams for SARS-CoV-2 Testing and Evaluation
A new home-assessment approach to evaluate patients for SARS-CoV-2 was described, which enables safe evaluation and specimen collection outside of healthcare settings.
Model Shows Combined Efforts May Cut SARS-CoV-2 Infections
Combined intervention of quarantine, school closure, workplace distancing projected to be most effective.
HPV Biomarkers, Survival Linked to High-Grade Esophageal Dysplasia, Adenocarcinoma
Low expression of the HPV-related marker cyclin D1 appears to be an independent prognostic marker in Barrett high-grade dysplasia and esophageal adenocarcinoma.
Dried Blood Spot Viral Load More Accurate Than Plasma Viral Load in HIV?
Dried blood spot viral load may be more accurate and useful than plasma viral load for patients with HIV in settings with limited resources.
Point-of-Care Test Shows Early Promise for Diagnosing Neurosyphilis
The point-of-care Dual Path Platform (DPP®) assay may be an inexpensive tool for the diagnosis of neurosyphilis.
Update on REMS-Required Testing During COVID-19 Pandemic
For patients suspected of having COVID-19, undergoing REMS-required testing to obtain a medication may put others at risk.
Women Less Likely to Receive Screening or Counseling For HIV at STI Diagnosis
Women are less likely to be tested for HIV or offered prep at time of sexually transmitted infection diagnosis.
FDA: Thermo Fisher COVID-19 Test Gets Emergency Use Authorization
The FDA has issued an Emergency Use Authorization to Thermo Fisher for its TaqPath COVID-19 Combo Kit, a diagnostic test that detects nucleic acid from SARS-CoV-2, the virus that causes coronavirus disease 2019.
Hepatocellular Carcinoma Prediction Beyond Year 5 of Therapy in Chronic Hepatitis B
A study identifies risk factors for hepatocellular carcinoma (HCC) after the first 5 years of receiving antiviral therapy in white patients with chronic hepatitis B.
Next post in Hepatitis Advisor
